The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?

The review examines the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on erectile function, particularly in men with type 2 diabetes and obesity-related hypogonadism. While some studies, such as those by Giagulli et al. and Jensterle et al., suggest that GLP-1 RAs like liraglutide can improve erectile function and metabolic parameters, others, like the study by Able et al., raise concerns about increased erectile dysfunction and testosterone deficiency with semaglutide use in non-diabetic men. The REWIND trial with 3,725 men indicated that dulaglutide reduced moderate/severe erectile dysfunction incidence. Overall, GLP-1 RAs show promise in improving erectile function, but further research is needed to confirm these findings and understand potential risks.